Literature DB >> 21576448

Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients.

Emi Minejima1, Joyce Choi, Paul Beringer, Mimi Lou, Edmund Tse, Annie Wong-Beringer.   

Abstract

Acute kidney injury (AKI) associated with high-dose vancomycin (VAN) therapy is a clinical concern, but no uniform diagnostic criteria exist. The AKI Network (AKIN) proposed new criteria to diagnose AKI based on abrupt changes in serum creatinine or urine output. We conducted a prospective observational study to determine the incidence and severity of AKI and associated outcomes using the AKIN criteria versus traditional definitions. Eligible patients (n = 227) were elderly (median, 70 years) and received VAN therapy for 8 days (median). AKI occurred in 43 patients (19%) using AKIN criteria at an onset of 6 days. AKI incidence was similar for patients with a trough level of ≥15 (24%; 17/72) versus <15 (17%; 26/155) μg/ml. Compared to non-AKI patients, more AKI patients resided in the intensive care unit (ICU) (47% [20/43] versus 27% [50/184]; P = 0.017), had a prior AKI episode (19% [8/43] versus 7% [5/184]; P = 0.001), and received vasopressor (28% [12/43] versus 14% [25/184]; P = 0.04) and/or nephrotoxins (84% [36/43] versus 67% [123/184]; P = 0.04). Seventeen of the AKI patients met traditional criteria, of whom more patients had stage 2 and 3 AKI (76% versus 8%; P = 0.0001), dosage adjustment (41% versus 15%) and renal consultation (35% versus 12%), prolonged length of stay after AKI (11 versus 7.5 days) and died (29% versus 12%) than those diagnosed by AKIN criteria (P value not significant). Use of AKIN criteria for AKI has the potential to improve care of VAN-treated patients by facilitating early detection of AKI and warrants confirmation in large prospective trials.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21576448      PMCID: PMC3122454          DOI: 10.1128/AAC.00173-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.

Authors:  Levita K Hidayat; Donald I Hsu; Ryan Quist; Kimberly A Shriner; Annie Wong-Beringer
Journal:  Arch Intern Med       Date:  2006-10-23

Review 2.  Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy.

Authors:  Annie Wong-Beringer; Julianne Joo; Edmund Tse; Paul Beringer
Journal:  Int J Antimicrob Agents       Date:  2010-12-03       Impact factor: 5.283

3.  Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion.

Authors:  Doris Hutschala; Christian Kinstner; Keso Skhirdladze; Florian Thalhammer; Markus Müller; Edda Tschernko
Journal:  Anesthesiology       Date:  2009-08       Impact factor: 7.892

Review 4.  Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis.

Authors:  Steven G Coca; Bushra Yusuf; Michael G Shlipak; Amit X Garg; Chirag R Parikh
Journal:  Am J Kidney Dis       Date:  2009-04-05       Impact factor: 8.860

5.  A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.

Authors:  Meghan N Jeffres; Warren Isakow; Joshua A Doherty; Scott T Micek; Marin H Kollef
Journal:  Clin Ther       Date:  2007-06       Impact factor: 3.393

Review 6.  Biomarkers of acute kidney injury.

Authors:  Vishal S Vaidya; Michael A Ferguson; Joseph V Bonventre
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

7.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.

Authors:  Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

Review 8.  Clinical review: RIFLE and AKIN--time for reappraisal.

Authors:  Dinna N Cruz; Zaccaria Ricci; Claudio Ronco
Journal:  Crit Care       Date:  2009-06-25       Impact factor: 9.097

9.  Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates.

Authors:  Christine Dieterich; Angela Puey; Sylvia Lin; Sylvia Lyn; Robert Swezey; Anna Furimsky; David Fairchild; Jon C Mirsalis; Hanna H Ng
Journal:  Toxicol Sci       Date:  2008-10-16       Impact factor: 4.849

Review 10.  Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.

Authors:  Rinaldo Bellomo; Claudio Ronco; John A Kellum; Ravindra L Mehta; Paul Palevsky
Journal:  Crit Care       Date:  2004-05-24       Impact factor: 9.097

View more
  31 in total

Review 1.  Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.

Authors:  Sepideh Elyasi; Hossein Khalili; Simin Dashti-Khavidaki; Amirhooshang Mohammadpour
Journal:  Eur J Clin Pharmacol       Date:  2012-03-13       Impact factor: 2.953

2.  Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats.

Authors:  Nathaniel J Rhodes; Walter C Prozialeck; Thomas P Lodise; Natarajan Venkatesan; J Nicholas O'Donnell; Gwendolyn Pais; Cameron Cluff; Peter C Lamar; Michael N Neely; Anil Gulati; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

3.  Effect of Vancomycin-Associated Acute Kidney Injury on Incidence of 30-Day Readmissions among Hospitalized Veterans Affairs Patients with Skin and Skin Structure Infections.

Authors:  Nimish Patel; Nicholas Stornelli; Ryan J Sangiovanni; David B Huang; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 4.  Mechanisms of antimicrobial-induced nephrotoxicity in children.

Authors:  Kevin J Downes; Molly Hayes; Julie C Fitzgerald; Gwendolyn M Pais; Jiajun Liu; Nicole R Zane; Stuart L Goldstein; Marc H Scheetz; Athena F Zuppa
Journal:  J Antimicrob Chemother       Date:  2020-01-01       Impact factor: 5.790

5.  24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury.

Authors:  J Nicholas O'Donnell; Nathaniel J Rhodes; Thomas P Lodise; Walter C Prozialeck; Cristina M Miglis; Medha D Joshi; Natarajan Venkatesan; Gwendolyn Pais; Cameron Cluff; Peter C Lamar; Seema Briyal; John Z Day; Anil Gulati; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 6.  Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter.

Authors:  S J van Hal; D L Paterson; T P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2012-11-19       Impact factor: 5.191

Review 7.  Prevention of vancomycin induced nephrotoxicity: a review of preclinical data.

Authors:  Sepideh Elyasi; Hossein Khalili; Shima Hatamkhani; Simin Dashti-Khavidaki
Journal:  Eur J Clin Pharmacol       Date:  2012-09-21       Impact factor: 2.953

8.  Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy.

Authors:  Claire Contreiras; Michael Legal; Tim T Y Lau; Rosanne Thalakada; Stephen Shalansky; Mary H H Ensom
Journal:  Can J Hosp Pharm       Date:  2014-03

9.  Nephrotoxicity comparison of two commercially available generic vancomycin products.

Authors:  Jesse D Sutton; Ryan P Mynatt; Keith S Kaye; Kyle P Murray; Michael J Rybak; Jason M Pogue
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

10.  Which risk predictors are more likely to indicate severe AKI in hospitalized patients?

Authors:  Lijuan Wu; Yong Hu; Borong Yuan; Xiangzhou Zhang; Weiqi Chen; Kang Liu; Mei Liu
Journal:  Int J Med Inform       Date:  2020-09-11       Impact factor: 4.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.